<html>
 <body>
  <div class="col-md-12" id="content" style="">
   <div class="hidden" data-drupal-messages-fallback="">
   </div>
   <div class="widget block" id="block-medsites-page-title">
    <h1>
     <span property="schema:name">
      CHF
     </span>
    </h1>
   </div>
   <div class="widget block" id="block-medsites-content">
    <article about="/commodorecompendium/chf" data-history-node-id="1037" role="article" typeof="schema:WebPage">
     <div>
      <div class="field field--name-body field--type-text-with-summary field--label-hidden field__item" property="schema:text">
       <div class="WordSection1">
        <div style="border-bottom:solid windowtext 1.0pt; border-top:double windowtext 1.5pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:107%">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="line-height:107%">
                 <span style="font-family:Palatino">
                  Congestive Heart Failure - Madeleine Alder
                 </span>
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:107%">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="background:white">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Background
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                HFrEF
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Ischemic
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  (40%): Obstructive CAD, previous/current myocardial infarction
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  NICM
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  (60%): HTN, idiopathic, myocarditis, genetic/familial, valvular, tachycardia/PVC-induced, infiltrative (amyloid, sarcoid, hemochromatosis), Takotsubo/stress cardiomyopathy, peripartum CM, substance abuse, chemotherapy/toxin-induced, "burned out" hypertrophic cardiomyopathy
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                HFpEF
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                :
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                HTN
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                , CAD, obesity, DM, infiltrative, hypertrophic cardiomyopathy
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Causes
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                of Heart Failure Exacerbations (
                <b>
                 FAILURES
                </b>
                )
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <b>
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Forgetting
                  </span>
                 </span>
                </b>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  medications or
                  <b>
                   taking
                  </b>
                  drugs that can worsen HF (e.g. BB, CCB, NSAIDs, TZDs), chemo (anthracyclines, trastuzumab)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <b>
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Arrhythmia
                  </span>
                 </span>
                </b>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  : AF, VT, PVCs; Increased arrhythmia burden on device check?
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <b>
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Ischemia or Infarction or Infection
                  </span>
                 </span>
                </b>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  ; myocarditis; Acute vascular dysfunction (e.g. endocarditis), especially mitral or aortic regurgitation.
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <b>
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Lifestyle choices
                  </span>
                 </span>
                </b>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  : Dietary indiscretions - high salt, EtOH, excessive fluid intake. Obesity.
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <b>
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Upregulation
                  </span>
                 </span>
                </b>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  (pregnancy and hyperthyroidism)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <b>
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Renal failure
                  </span>
                 </span>
                </b>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  : acute, progression of CKD, or insufficient dialysis (Increased preload)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <b>
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Embolus
                  </span>
                 </span>
                </b>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  (pulmonary) or COPD (leads to increase right-sided afterload)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <b>
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Stenosis
                  </span>
                 </span>
                </b>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  (worsening AS, RAS) leading to hypertensive crisis
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Wingdings">
                  
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  high left-sided afterload
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
        </ul>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:107%">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="line-height:107%">
               <span style="font-family:Palatino">
                Presentation
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Congestion
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                : shortness of breath, dyspnea on exertion, Orthopnea, PND
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Nausea
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                /poor po intake
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Confusion
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Exam
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                : Edema (legs, sacrum); Rales, S3, S4, murmur (AS, MR), Elevated JVD, + Hepatojugular reflex, Ascites
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:107%">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="line-height:107%">
               <span style="font-family:Palatino">
                Evaluation
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
       </div>
       <div class="WordSection2">
        <ul>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                CBC
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                , CMP, Magnesium
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Lactate, Troponin, BNP
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Pro-BNP if on Entresto)
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                TSH
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Iron studies
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                EKG
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                CXR, TTE
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Determine Hemodynamic Profile
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
       </div>
       <div class="WordSection3">
        <p>
        </p>
        <table class="TableGrid1" style="width:100.0%; border-collapse:collapse; border:none" width="100%">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
      <th>3</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Volume Status</td>
      <td>Volume Status</td>
      <td>Euvolemia</td>
      <td>Hypervolemia</td>
    </tr>
    <tr>
      <td>Normal  Cardiac Index</td>
      <td>Warm Extremities  Adequate Urine Output  Normal Pulse Pressure</td>
      <td>Warm and Dry Forrester Class I</td>
      <td>Warm and Wet Forrester Class II</td>
    </tr>
    <tr>
      <td>Low  Cardiac Index</td>
      <td>Cardiogenic Shock  Cool Extremities  Renal Failure  Narrow Pulse Pressure</td>
      <td>Cold and Dry Forrester Class III</td>
      <td>Cold and Wet Forrester Class IV</td>
    </tr>
  </tbody>
</table>
        </table>
        <p>
         <br/>
         <span style="page:WordSection3">
          <span style="font-size:11pt">
           <span style="line-height:107%">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="line-height:107%">
               <span style="font-family:Palatino">
                Management
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Telemetry
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                , Daily STANDING weights, 2 L fluid restriction, 2g sodium diet, Strict I/Os
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Cold
                </span>
               </span>
              </b>
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 and Wet
                </span>
               </span>
              </b>
              <span style="font-size:12.0pt">
               <span style="font-family:Wingdings">
                à
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                may require ionotropic support or transfer to the CCU
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Warm and Wet
                </span>
               </span>
              </b>
              <span style="font-size:12.0pt">
               <span style="font-family:Wingdings">
                à
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Diuresis
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Diuresis
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  : Place on 2.5 x home dose of IV diuretic, dose BID-TID (DOSE Trial)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
            <ul style="list-style-type:disc">
             <li>
              <span style="page:WordSection3">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    Goal is to be net negative (generally 1-2 L per day, but patient dependent)
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection3">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    Check BMP and Mg BID and keep K>4 and Mg>2
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection3">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    Monitor UOP and weights to determine if dosing adequate
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection3">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    Low threshold for substantial increase (double) in loop vs transition to drip
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection3">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <wrapblock>
                   <shape filled="f" id="Text_x0020_Box_x0020_2" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" strokecolor="windowText" style="position:absolute; left:0; text-align:left; margin-left:5px; margin-top:18px; width:252pt; height:15.65pt; text-indent:0; z-index:-251656192; v-text-anchor:middle" type="#_x0000_t202">
                    <textbox>
                    </textbox>
                   </shape>
                  </wrapblock>
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    Can also augment with sequential nephron blockade (thiazides, acetazolamide)
                   </span>
                  </span>
                  <wrapblock>
                   <shape filled="f" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" strokecolor="windowText" style="position:absolute; left:0; text-align:left; margin-left:5px; margin-top:18px; width:252pt; height:15.65pt; text-indent:0; z-index:-251656192; v-text-anchor:middle" type="#_x0000_t202">
                    <textbox>
                    </textbox>
                   </shape>
                  </wrapblock>
                 </span>
                </span>
               </span>
              </span>
             </li>
            </ul>
           </li>
          </ul>
         </li>
        </ul>
       </div>
       <p>
       </p>
       <div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
        <p style="border:none; padding:0in">
         <span style="font-size:11pt">
          <span style="line-height:107%">
           <span style="font-family:Calibri,sans-serif">
            <b>
             <span style="font-size:12.0pt">
              <span style="line-height:107%">
               <span style="font-family:Palatino">
                Goal-Directed Medical Therapy
               </span>
              </span>
             </span>
            </b>
           </span>
          </span>
         </span>
        </p>
       </div>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:107%">
          <span style="font-family:Calibri,sans-serif">
           <b>
            <span style="font-size:12.0pt">
             <span style="line-height:107%">
              <span style="font-family:Palatino">
               ACE-Inhibitors/ARBs
              </span>
             </span>
            </span>
           </b>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Blocks harmful effects of renin-angiotensin-aldosterone system activation and attenuates adverse cardiac and vascular remodeling
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              If planning on using Entresto eventually, favor ARB over ACE-i in short term
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Sacubitril-valsartan (Entresto):  Additional benefit of Neprilysin inhibition
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                36-hour washout after stopping ACE-i before starting Entresto to avoid angioedema
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
       </ul>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:107%">
          <span style="font-family:Calibri,sans-serif">
           <b>
            <span style="font-size:12.0pt">
             <span style="line-height:107%">
              <span style="font-family:Palatino">
               Aldosterone receptor antagonists
              </span>
             </span>
            </span>
           </b>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Diuretic and blood pressure lowering effects and blocks deleterious effects of aldosterone on the heart (including hypertrophy and fibrosis)
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              May also reduce hospitalizations in HFpEF
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Worry about hyperkalemia: avoid if CrCl<30 or K>5
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:107%">
          <span style="font-family:Calibri,sans-serif">
           <b>
            <span style="font-size:12.0pt">
             <span style="line-height:107%">
              <span style="font-family:Palatino">
               Beta-blockers
              </span>
             </span>
            </span>
           </b>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Reduces catecholamine stimulation including elevated heart rate, increased myocardial energy demands, adverse remodeling due to cardiac myocyte hypertrophy and death
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Mortality benefit shown with carvedilol, metoprolol succinate or bisoprolol
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Avoid if pt is decompensated (cold); “start low and go slow”
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Can continue during exacerbation if patient compensated, (ie not in shock)
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:107%">
          <span style="font-family:Calibri,sans-serif">
           <b>
            <span style="font-size:12.0pt">
             <span style="line-height:107%">
              <span style="font-family:Palatino">
               Hydralazine/Isosorbide Dinitrate
              </span>
             </span>
            </span>
           </b>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Reduces cardiac afterload and preload and may also enhance nitric oxide bioavailability
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Reduction in mortality for African American patients
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:107%">
          <span style="font-family:Calibri,sans-serif">
           <b>
            <span style="font-size:12.0pt">
             <span style="line-height:107%">
              <span style="font-family:Palatino">
               SGLT-2 inhibitors
              </span>
             </span>
            </span>
           </b>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Osmotic diuresis and natriuresis, improve myocardial metabolism, inhibit sodium-hydrogen exchange in myocardium, reduce cardiac fibrosis
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:107%">
          <span style="font-family:Calibri,sans-serif">
           <b>
            <span style="font-size:12.0pt">
             <span style="line-height:107%">
              <span style="font-family:Palatino">
               Cardiac resynchronization therapy (CRT)
              </span>
             </span>
            </span>
           </b>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Criteria: HFrEF with LVEF ≤35%, QRS ≥150 ms with left bundle branch block (LBBB); NYHA class II to ambulatory class IV HF and wide QRS
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:107%">
          <span style="font-family:Calibri,sans-serif">
           <b>
            <span style="font-size:12.0pt">
             <span style="line-height:107%">
              <span style="font-family:Palatino">
               Mitra Clip
              </span>
             </span>
            </span>
           </b>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Criteria: mitral regurgitation of 3-4+, on maximally tolerated GDMT, an ejection fraction >20%, and a left ventricle end-systolic dimension of less than 7 cm
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:107%">
          <span style="font-family:Calibri,sans-serif">
           <b>
            <span style="font-size:12.0pt">
             <span style="line-height:107%">
              <span style="font-family:Palatino">
               Iron
              </span>
             </span>
            </span>
           </b>
           <b>
            <span style="font-size:12.0pt">
             <span style="line-height:107%">
              <span style="font-family:Palatino">
               repletion
              </span>
             </span>
            </span>
           </b>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Criteria: ferritin <100 µg/L or ferritin 100-299 µg/L AND transferrin saturation <20%.
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Replete intravenous (IV) iron. IV iron sucrose (500 mg x2 doses 48 hours apart) or ferric carboxymaltose (maximum dose of 1000 mg per week) or iron dextran (1 g x1)
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:107%">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="line-height:107%">
             <span style="font-family:Palatino">
              Additional Information:
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <b>
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               ICD placement (See Below, eg
               <a href="https://medsites.vumc.org/commodorecompendium/cardiac-devices">
                Cardiac Devices
               </a>
               )
              </span>
             </span>
            </b>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Starting patients on low dose of multiple agents preferred to max dose of single agent
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              D/C summary should have discharge weight, diuretic regimen, and renal function
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Daily weights at home with rescue diuretic plan (pm dose for 3 lbs in 1 day, 5 lbs in 3 days)
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
      </div>
     </div>
    </article>
   </div>
  </div>
 </body>
</html>